Developed initially to manage diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in popularity ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...

The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the ...

The following is a summary of “Endoscopy and Anesthesia Outcomes Associated with Glucagon-Like Peptide-1 Receptor Agonist Use ...

There’s a little problem, though: most of the decline in the seven comes down to one company. Apple is down 14 per cent since ...

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders.

Colorado plans to limit insurance coverage for weight-loss drugs like Wegovy and Ozempic for thousands of state employees.

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have been ...

A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.

Vendors such as Color Health promise to save employers money by helping workers catch cancer sooner, but these initiatives ...